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Abstract
The annonaceous acetogenins are the most potent of the known inhibitors of bovine heart mitochondrial complex I. These
inhibitors act, at the terminal electron transfer step of the enzyme, in a similar way to the usual complex I inhibitors, such as
piericidin A and rotenone; however, structural similarities are not apparent between the acetogenins and these known
complex I inhibitors. A systematic set of isolated natural acetogenins was prepared and examined for their inhibitory actions
with bovine heart mitochondrial complex I to identify the essential structural factors of these inhibitors for the exhibition of
potent activity. Despite their very potent activity, the structural requirements of the acetogenins are not particularly rigid and
remain somewhat ambiguous. The most common structural units, such as adjacent bis-tetrahydrofuran (THF) rings and
hydroxyl groups in the 4- and/or 10-positions, were not essential for exhibiting potent activity. The stereochemistry
surrounding the THF rings, surprisingly, seemed to be unimportant, which was corroborated by an exhaustive
conformational space search analysis, indicating that the model compounds, with different stereochemical arrangements
around the THF moieties, were in fairly good superimposition. Proper length and flexibility of the alkyl spacer moiety, which
links the THF and the K,L-unsaturated Q-lactone ring moieties, were essential for the potent activity. This probably results
from some sort of specific conformation of the spacer moiety which regulates the two ring moieties to locate into an optimal
spatial position on the enzyme. It is, therefore, suggested that the structural specificity of the acetogenins, required for
optimum inhibition, differs significantly from that of the common complex I inhibitors in which essential structural units are
compactly arranged and conveniently defined. The structure^activity profile for complex I inhibition is discussed in
comparison with those for other biological activities. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
A large number of natural acetogenins have been
isolated from several genera of the plant family, An-
nonaceae [1,2]. Many of these compounds have di-
verse biological e¡ects, such as cytotoxic, in vivo
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antitumor, antimalarial, pesticidal, and antifeedant
activities [3^5]. In particular, the inhibitory e¡ect of
acetogenins on mitochondrial NADH-ubiquinone
oxidoreductase (complex I) is worthy of notice not
only because some of the compounds, such as bulla-
tacin and rolliniastatin 1, are the most potent inhib-
itors of the enzyme so far known [6^8], but also
because it is quite di⁄cult to visualize structural sim-
ilarities between the acetogenins and usual complex I
inhibitors, such as piericidin A and rotenone; yet, the
acetogenins act at the terminal electron transfer step
of complex I (i.e. between Fe-S cluster 2 and the
ubiquinone pool) similar to the usual complex I in-
hibitors [6,7,9].
The annonaceous acetogenins are fairly large mol-
ecules compared to the ordinary complex I inhibitors
including the newer potent agrochemicals, such as
fenpyroximate and SAN548A. The average length
of the acetogenin molecules is about twice that of
piericidin A when they are compared in an extended
conformation. The structural speci¢city of these ace-
togenins is that the two functional units (i.e. the hy-
droxylated tetrahydrofuran (THF) and K,L-unsatu-
rated Q-lactone ring moieties) are separated by a
long alkyl chain, although the two moieties could
each play signi¢cant roles in binding interactions to
the enzyme. Thus, considering the unusual structural
characteristics as well as the markedly strong inhib-
itory potency of acetogenins, the study of the action
of these inhibitors is important to elucidate structural
and functional features of the terminal electron
transfer step of complex I. As the ¢rst step toward
this purpose, the identi¢cation of the essential struc-
tural factors of the acetogenins for exhibiting the
most potent inhibition is earnestly required.
In general, to identify important structural factors
of biologically active compounds based on their
structure^activity relationships, a series of derivatives
is needed in which chemical structures are widely and
systematically modi¢ed. Several structure^activity
studies of acetogenins for complex I inhibition have
been carried out [6^8,10^12]; the important structur-
al factors have not been fully de¢ned yet, and only
limited structural variations of the acetogenins have
been tested previously. Since total syntheses of a va-
riety of acetogenins is still di⁄cult [13^16], we have
utilized structurally diverse representatives of the ser-
ies of isolated natural products that we have avail-
able. In this study, we prepared a systematic set of
such isolated natural acetogenins (Fig. 1) among
which comparisons of activity changes of closely re-
lated derivatives is feasible, and we have examined
their inhibition of bovine heart mitochondrial com-
plex I. This study is the ¢rst detailed structure^activ-
ity study of the acetogenins for the inhibition of mi-
tochondrial complex I, and it has revealed several
interesting structural factors of the acetogenins re-
quired for the potent inhibition of this enzyme.
2. Materials and methods
2.1. Materials
Antimycin A was purchased from Sigma. MOA-
stilbene was provided by Aburahi Laboratories,
Shionogi (Shiga, Japan). Q1 (ubiquinone-1) was a
generous gift from Eisai (Tokyo, Japan). Piericidin
A was generously provided by Dr. Shigeo Yoshida
(RIKEN, Japan). Diethoxy-Q2 (2,3-diethoxy-6-ger-
anyl-5-methyl-1,4-benzoquinone) was from a pre-
vious sample [17]. Other chemicals were commercial
products of analytical grade.
2.2. Preparation of acetogenins
The acetogenins used in this study (Fig. 1) were
isolated from ethanol extracts of various annona-
ceous plants [1^3]. The purity of the acetogenins
was chromatographically (thin-layer and HPLC)
and spectroscopically (1H- and 13C-NMR spectros-
copy) con¢rmed. NMR spectra were recorded on a
Bruker ARX-300 and a Varian VXR-500.
2.3. Methods
Bovine heart submitochondrial particles (SMP)
were prepared by the method of Matsuno-Yagi and
Hate¢ [18] using a sonication medium containing
0.25 M sucrose, 1 mM succinate, 1.5 mM ATP, 10
mM MgCl2, 10 mM MnCl2 and 10 mM Tris-HCl
(pH 7.4), and stored in a bu¡er containing 0.25 M
sucrose and 10 mM Tris-HCl (pH 7.4) at 378‡C.
The NADH oxidase activity was followed spectro-
metrically with a Shimadzu UV-3000 at 340 nm
(O= 6.2 mM31 cm31) at 30‡C. The reaction medium
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contained 0.25 M sucrose, 1 mM MgCl2 and 50 mM
phosphate bu¡er (pH 7.4). The ¢nal mitochondrial
protein concentration was 30 Wg of protein/ml. The
reaction was started by adding 50 WM NADH after
SMP were equilibrated with inhibitor for 5 min. The
NADH-Q oxidoreductase activity was determined
following NADH oxidation at 30‡C in the same re-
action medium in the presence of indicated concen-
trations of exogenous Q, 0.2 WM antimycin A, 0.2
WM MOA-stilbene and 2 mM KCN.
3. Results
Acetogenin molecules investigated in this study
can be dissected into four chemical portions, for sim-
plicity, as follows: the hydroxylated THF ring moi-
ety, the K,L-unsaturated Q-lactone ring moiety, the
spacer moiety linking the two rings, and the hydro-
phobic side chain attached to the THF ring(s) which
ends with the terminal methyl. We examined the
roles of each portion in exhibiting potent inhibitory
action with bovine complex I. The inhibitory poten-
cies of all compounds in terms of the I50 value, which
is the molar concentration in the reaction medium
needed to inhibit one-half of the control enzyme
(NADH oxidase) activity, are listed in Table 1.
3.1. The role of the stereochemistry and number of the
THF rings
Compound 1 (bullatacin) was revealed to be more
potent than piericidin A, and, as noted previously, it
was also one of the most potent acetogenins with
bovine complex I [6,7]. We con¢rmed that compound
1 is about two-times more potent than piericidin A
when the I50 values were compared under the present
experimental conditions. A di¡erent structural factor
between compounds 1 and 2 (trilobacin) is solely the
con¢guration of the adjacent bis-THF ring moiety.
The inhibitory potencies of the two compounds were
almost identical, taking into account experimental
errors. This indicated that the stereochemical ar-
rangement of the bis-THF ring was not an essential
structural factor for potent activity. This notion
would be supported by the earlier observation that
the potencies of rolliniastatin 1 and bullatacin, which
also di¡er from each other only in the stereochemical
arrangement of the THF rings, are almost identical
[6]. In [6], the authors emphasized a slight di¡erence
in the inhibitory potencies of rolliniastatin 1 and
bullatacin, whereas the I50 and Ki values of the two
compounds would be taken as almost identical, con-
sidering experimental variations in their work (see
Figs. 2 and 3 in [6]). Three-dimensional structural
features of the hydroxylated adjacent bis-THF moi-
eties are not so di¡erent between the two stereoiso-
mers, as discussed later.
Compounds 8 (sylvaticin) and 9 (bullatalicin) re-
tained the potent activity despite bearing di¡erent
con¢gurations in one of the two non-adjacent THF
rings. This ¢nding indicates not only that adjacent
bis-THF rings are not essential for the activity, but
also that the con¢gurations of the THF ring moieties
are not so important, as mentioned above (com-
pounds 1 vs. 2). In addition, the fact that the I50
value of compound 11 (muricatetrocin B) was almost
identical to that of the most potent inhibitors like
compound 1 indicates that the presence of a mono-
THF ring can be su⁄cient enough to retain the po-
tent activity.
To compare the three-dimensional structures of
the hydroxylated adjacent bis-THF rings between
stereoisomers, the method of exhaustive conforma-
tional space search [19] was employed for model
compounds A and B (Fig. 2) which are component
Table 1
Summary of inhibitory potencies of acetogenins
Compound no. I50 (nM) Compound no. I50 (nM)
1 1.2 12 330
2 1.4 13 3.8
3 1.9 14 4.1
4 14 15 6.1
5 5.4 16 21
6 1.8 17 2.4
7 1.6 18 1.6
8 1.4 19 9.4
9 1.6 20 17
10 3.3 21 2.9
11 1.5 22 26
(Piericidin A) 2.1
The I50 value is the molar concentration in the reaction medium
needed to halve the control NADH oxidase activity. The con-
trol enzyme activity was 0.55^0.60 Wmol NADH/min/mg of pro-
tein. The values were averaged from two independent measure-
ments.
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parts of compounds 1 and 2, respectively. In each
model compound, single bonds were rotated by the
step of 60‡, and 7776 initial conformations were op-
timized by quantum chemical calculations (MNDO-
AM1). A total of 185 and 169 stable conformations
were obtained for models A and B, respectively.
COMPASS (common geometrical pattern search sys-
tem) [20] followed by molecular ¢eld ¢tting was im-
plemented for all combinations of the stable confor-
mations of each molecule. Although stereochemical
arrangement of the left side moiety of the model
compounds is di¡erent, molecular ¢eld ¢tting re-
sulted in fairly good superimposition. In 1786 of
31 265 (=185U169) cases, the similarity index was
greater than 90%. Some of the best ¢ttings (i.e. sim-
ilarity index greater than 95%) are shown in Fig. 2.
These results strongly suggested that stereochemical
di¡erences of the bis-THF rings make little di¡erence
in the three-dimensional structure of this moiety.
Recently, Shimada et al. [21] reported that the
THF rings of the annonaceous acetogenins strongly
interact with the glycerol backbone region of lipids in
liposomal membranes, and it was proposed that the
THF rings may serve a role as an anchor in the
membrane to optimize the location and the confor-
mation of the functional group(s) of the acetogenins.
If the role of the THF rings is, indeed, as an anchor
at the interface of the membrane, the stereochemical
Fig. 1. Structures of acetogenins used in this study.
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di¡erences within the THF rings of the acetogenins
should not make much di¡erence in their bioactivity
pro¢les which agrees with the results of the COM-
PASS analysis.
3.2. The role of the length of the spacer moiety
Comparing the I50 values of compounds 1, 3 (par-
vi£orin) and 4 (longimicin C), clearly revealed that
the shorter the length of the spacer moiety, the weak-
er the potency becomes. This notion was also sup-
ported from comparisons of compounds 10 (gigante-
trocin A) vs. 11 (muricatetrocin B) and compounds
13 (annonacin) vs. 16 (goniothalamicin), wherein
structural features, such as total number of carbon
atoms, substituted positions of OH groups, and con-
¢guration of the THF moiety, are identical except
for the length of the spacer. Therefore, the spacer
moiety seems to regulate some sort of signi¢cant
spatial arrangement between the Q-lactone and THF
ring moieties irrespective of the number of the THF
rings.
3.3. The role of hydroxy groups in the spacer moiety
Compound 5 (longimicin D), in which the length
of the spacer is the same as that of compound 3 but
with one OH group moved from the 4-position to the
Fig. 1 (continued).
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10-position, was slightly less potent than compound
3. However, since the I50 value of compound 5 was
retained at the nM level, the 4-OH group itself seems
not to be essential for the activity. In support of this,
compounds 6 (squamocin B) and 7 (squamocin), in
which the positions of the third OH groups are in the
terminal alkyl chain at the 26- and 28-positions, re-
spectively, instead of between the two ring moieties,
maintained the potent activities. This conclusion was
valid irrespective of the number of the THF rings
(one or two) in the middle of the molecule, as seen
in compounds 13^15 and 17. In addition, compound
18 (annoreticuin-9-one) was rather more potent than
compound 13, though the only structural di¡erence
between them is that the 10-OH group of the latter is
transformed to 9-oxo in the former. This also indi-
cates that the common 4,10-dihydroxy substitution
pattern in the spacer moiety is not essential for the
potent activity.
Compound 12 (murihexocin), in which two addi-
tional OH groups are attached in the spacer moiety
of compound 11, appeared not only to be a much
poorer inhibitor than compound 11, but also to be
the poorest inhibitor among all of the compounds
evaluated in this study. This is probably because
the presence of the two vicinal OH groups in this
spacer region prevents the Q-lactone and THF ring
moieties from positioning into the optimal spatial
location suggested above. Considering that both
compounds 11 and 12 possess the same total number
of carbon atoms between the THF and the Q-lactone
rings, the alkyl chain length between the two ring
systems cannot be the reason for their di¡erent ac-
tivity pro¢les, but the di¡erence in their polarities in
their spacer regions would seem to be quite impor-
tant. Considering this and the above results, it seems
likely that no polar functional group is required
within the spacer moiety to retain the potent activity
and too many polar functional groups therein hinder
the activity.
The structural pro¢le of compounds 19 (aromin)
and 20 (aromicin) resemble compound 18, but these
compounds possess one THF ring within the spacer
moiety. The activities of compounds 19 and 20 were
decreased compared to that of compound 18. It can
be argued that the THF ring (located in the middle
of the molecule) and the Q-lactone ring are not cor-
rectly positioned for optimal spatial location due to
the presence of the rigid THF ring at positions 4^7.
This result also suggested that, when similar aceto-
genins possess the same number of carbons between
the THF and the Q-lactone ring systems, the di¡erent
chemical groups (a hydroxyl vs. a THF ring in this
Fig. 3. Hanes^Woolf plot of kinetics data of NADH-Q1 oxidor-
eductase activity in the presence of compound 1 (bullatacin).
The reaction medium, in a ¢nal volume of 2.5 ml, contained 50
mM phosphate bu¡er (pH 7.4), 0.25 M sucrose, 1 mM MgCl2,
50 WM Q1, 0.2 WM antimycin A, 0.2 WM MOA-stilbene and
2 mM KCN. The ¢nal mitochondrial protein concentration was
30 Wg of protein/ml. The reaction was started by adding 50 WM
NADH. The concentration of compound 1 was 0 nM (a), 0.9
nM (b) or 1.5 nM (F).
Fig. 2. Superimposition of model compounds A (solid line) and
B (dotted line). Model compounds A and B are the model of
the bis-THF rings moiety of compounds 1 (bullatacin) and 2
(trilobacin), respectively. The single bonds indicated by arrows
were rotated by the step of 60‡. Similarity index and conforma-
tion energy for each superimposition are shown below the view.
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case) in their spacer regions are responsible for their
di¡erent activity pro¢les.
3.4. The role of the length of the alkyl side chain
Compound 20 was 50% less active than compound
19, although the tail moiety of the former is longer
than that of the latter by two carbon atoms. This
¢nding indicates that if other structural factors are
identical, a less hydrophobic tail is favorable for the
activity. This tendency is also observed with the pair
of compounds 14 and 15. It can be suggested that 13
carbons in the tail moiety of compounds 19 and 14
are su⁄ciently hydrophobic, and a further increase in
hydrophobicity of the tail is rather adverse to the
activity due to some sort of trapping in the hydro-
phobic lipid bilayer of the membrane. Similar behav-
ior has been observed for very hydrophobic inhibi-
tors of respiratory enzymes, such as synthetic
antimycins [22] and piericidins [23]. It should be
mentioned, however, that this consideration does
not necessarily mean that a shorter tail structure
would be better for the activity.
3.5. Characterization of inhibitory action of
acetogenins
The inhibition mechanism of compound 1 (bulla-
tacin), the most potent acetogenin studied here, was
examined in the NADH-Q1 oxidoreductase assay
with a series of concentrations of Q1 added to the
system. As shown in Fig. 3, the inhibition mechanism
was non-competitive against Q1. Non-competitive in-
hibition was also suggested by other plots of the
experimental data, such as 1/[S] vs. 1/rate and rate/
[S] vs. rate. In support of this, the inhibitory potency
of this compound was not a¡ected irrespective of
which Q structure was used as an electron acceptor,
as shown in Fig. 4. Complete inhibition was attained
in the presence of about 2 nM of compound 1 in all
cases. Although a titration curve was almost linear
when exogenous Q (Q1 or diethoxy-Q2) was used as
an electron acceptor, that for the NADH oxidase
activity (closed circles) was slightly sigmoidal. A sim-
ilar sigmoidal titration curve was observed with roll-
iniastatin 1 in the earlier study [8], whereas the rea-
son for this remains to be elucidated. The fact that
the sensitivity of bulky diethoxy-Q2 to the inhibition
by compound 1 was similar, but not identical, to that
of endogenous Q (Q10) supports the previous ¢nding
that this bulky substrate accepts electrons from the
physiological site of the enzyme [17].
We also performed the same experiments for com-
pounds 12 and 18. Similarly to compound 1, the
inhibition mechanism of these two compounds was
non-competitive against Q1 despite a large di¡erence
in the inhibitory potencies, and their inhibitory po-
tencies were not a¡ected irrespective of which Q
structure was used as an electron acceptor (data
not shown).
Earlier studies [6,11] investigated the Dixon plot
analysis to determine the mutual exclusivity between
acetogenins as well as between acetogenins and rote-
Fig. 5. Dixon plots of compound 1 (bullatacin) in the presence
of rotenone. NADH oxidase activity was determined under the
experimental conditions given in Fig. 4. Rotenone concentra-
tions were 0 nM (a), 1.4 nM (F) and 2.7 nM (b).
Fig. 4. The inhibition of electron transfer by compound 1 (bul-
latacin) with various ubiquinones. For NADH-Q oxidoreduc-
tase activity, the reaction conditions were the same as in the
legend to Fig. 3. As an electron acceptor, 50 WM Q1 (E) or 100
WM 2,3-(EtO)2-Q2 (F) was used. The inhibition of NADH oxi-
dase activity (b) was also examined under the same reaction
conditions, except that complexes III and IV inhibitors were
omitted from the reaction medium. The extent of inhibition at-
tained by 0.1 WM piericidin A was taken as 100% inhibition.
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none. We carried out the same analysis by titrating
compound 1 in the presence of di¡erent ¢xed con-
centrations of rotenone which exhibited inhibition
less than 50%. As shown in Fig. 5, the plots were
curvilinear especially in the region of high concentra-
tions of compound 1. Extrapolation of the linear
part of the plots at the low concentration range
gave the common intercept at the x-axis (dotted
lines), suggesting that compound 1 and rotenone
are mutually non-exclusive inhibitors. Although this
result seems to be consistent with the earlier obser-
vations [6,11], the Dixon plot analysis should be in-
terpreted with care since the extrapolated straight
line is signi¢cantly a¡ected depending upon the re-
gion of inhibitor concentrations of interest, as readily
realized from Fig. 5. The earlier studies did not men-
tion this, and the Dixon plots therein were linearly
extrapolated throughout all inhibitor concentrations.
To draw precise conclusions about the mutual exclu-
sivity between acetogenins as well as between aceto-
genins and rotenone, radioligand assay is required.
4. Discussion
The annonaceous acetogenins, which are previ-
ously reported to be the most potent complex I in-
hibitors, are those with adjacent bis-THF rings in the
middle of the molecules [6^8]. The present structure^
activity study clearly indicates that the adjacent bis-
THF ring moiety is not an essential structural factor
for exhibiting potent inhibition, and the mono-THF
ring compounds can maintain the potent activity.
The natural acetogenins have various stereochemical
con¢gurations around the hydroxylated THF ring
moiety. This stereochemical factor was also not es-
sential for potent activity irrespective of the number
(one or two) of THF rings. This conclusion seemed
to be supported by the exhaustive conformational
space research study, which revealed that some stable
conformations of the adjacent bis-THF rings of ster-
eoisomers overlapped well. This conclusion also
agrees with the observation by Shimada et al. [21]
that the THF rings of the acetogenins had strong
interactions with the interface of lipid bilayers irrel-
evant with the stereochemistry of the THF region.
The presence of the 4- and/or 10-OH groups in the
spacer region was also not essential for the activity.
It seems that no polar substituent is required in this
moiety.
On the other hand, it was demonstrated that the
spacer moiety is very important for the potent activ-
ity. This ¢nding, however, does not necessarily indi-
cate that the distance, itself, between the THF ring(s)
and the K,L-unsaturated Q-lactone ring is important
for the activity, since the activities of the compounds
which have the same or similar number of carbon
atoms in the spacer often di¡ered markedly (com-
pounds 11 vs. 12 and compounds 18 vs. 19). If an
extended conformation of the spacer moiety would
be an active conformation, activities of the com-
pounds which possess alkyl spacers of less than 13
carbon atoms, such as compounds 3, 4 and 16,
would be reduced more drastically than those pos-
sessing alkyl chains of 13 carbon atoms, but the re-
sults were not so. Therefore, some sort of speci¢c
conformation of the spacer might regulate the two
ring moieties to locate into an optimal spatial posi-
tion which is essential to elicit the most potent inhib-
ition. The design syntheses of acetogenins, in which
the spatial position of the two ring moieties could be
¢xed to each other in di¡erent manners by speci¢c
structures of the spacer, would be helpful to elucidate
the optimal conformation of the acetogenin molecule
as well as the function of the spacer.
There are several structure^activity studies of very
potent inhibitors of respiratory enzymes, such as
antimycin A, stigmatellin, and piericidin A, which
completely inhibit the enzyme activity at stoichiomet-
ric amounts with respect to their target enzymes (i.e.
complex I or III). For these inhibitors, essential
structural factors which a¡ect the inhibitory potency
by several orders of magnitude have been identi¢ed.
For instance, a phenolic hydroxyl group of the sali-
cylic acid moiety of antimycin A is essential for the
potent activity since methylation of this functional
group resulted in marked reduction of the potency
by about four orders of magnitude [24,25]. Methyl-
ation of the pyridinol hydroxyl group of piericidin A
reduced the potency by about 500-fold [26]. Modi¢-
cation of either the 8-hydroxy or the 4-oxo groups of
the chromone ring system of stigmatellin a¡ect the
potency by three orders of magnitude [27]. Consid-
ering these facts, the structure^activity pro¢le of ace-
togenins revealed in this study seems to be unusual
since marked changes in the inhibitory potency (say,
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by several orders of magnitudes) due to single struc-
tural modi¢cations were not observed except for
compound 12. Although an important role of the
spacer moiety was revealed, other derivatives wherein
the structures of the THF ring and/or the K,L-un-
saturated Q-lactone moieties are widely modi¢ed,
are required to know whether these common struc-
tural units are essential for the potent activity.
Concerning this respect, it should be noted that
the number of isolated natural acetogenins in which
the THF and/or the K,L-unsaturated Q-lactone
moieties are deleted or modi¢ed is highly limited.
However, we isolated two unusual compounds (com-
pounds 21 (gigantetroneninone) and 22 (venezinone))
and investigated their activity as a preliminary ex-
amination to ¢nd a clue to the above issue. Both
compounds have ketolactones in place of the K,L-
unsaturated Q-lactone, and compound 22 has no
THF ring in the middle of the molecule. The fact
that the I50 value of compound 21 was retained at
the nM level suggested that the common K,L-unsatu-
rated Q-lactone is not really essential for potent ac-
tivity. Although the length between the THF ring
and the ketolactone of compound 21 is rather shorter
than that of compounds 4 and 10, the former was
more potent than the latter two. This suggests that
the role of the spacer moiety might di¡er somewhat
between the K,L-unsaturated Q-lactone and the keto-
lactone compounds. The potency of compound 22
decreased to about 1/10th that of compound 21, sug-
gesting that the THF ring is important to maintain
the most potent activity, but it is not essential for
eliciting the inhibition. Further derivatives are
needed to draw conclusions on the functions of the
THF ring and the K,L-unsaturated Q-lactone.
An earlier study [6] reported that the acetogenins
inhibit complex I activity in non-competitive or un-
competitive manners against exogenous Q depending
upon inhibitor structures. The inhibition by bullata-
cin (compound 1) was uncompetitive against exoge-
nous Q [6,11]. In contrast to this, the present study
showed that the inhibition manner of acetogenins is
non-competitive against Q1 irrespective of the inhib-
itor structures. Although we have no proper explan-
ation for this discrepancy, it could be mentioned that
the inhibition mechanism was investigated in the ear-
lier studies at a certain concentration of the inhibitor
which elicits a fairly large extent of inhibition (i.e. at
low residual enzyme activity). In addition, although
the previous studies [6,11] discussed the binding man-
ners (or sites) of acetogenins in relation to the pro-
posed multiple Q binding sites model [28,29], we
think that this model should be inferred by further
experimental evidence1 and such classi¢cation is im-
practical at present.
The structure^activity pro¢le of acetogenins re-
vealed in this study seems to be comparable to that
observed for the inhibition of the growth of adria-
mycin resistant human mammary adenocarcinoma
(MCF-7/Adr) cells [5] and the yellow fever mosquito
larvae microtiter plate assay [30]. For example, con-
clusions about the structure^activity relationships
with MCF-7/Adr cells can be drawn as follows: (1)
a hydroxyl group at the 4-position is not required as
long as there are a total of three hydroxyl groups in
the bis-adjacent THF series; (2) distance of not less
than 13 carbon atoms in the spacer moiety is opti-
mum; and (3) the non-adjacent bis-THF ring and
mono-THF compounds have similar potencies to
the bis-adjacent THF compounds. The similar struc-
ture^activity pro¢les between complex I and MCF-7/
Adr cells would be explained by the fact that the
ability of the acetogenins to lower ATP levels, via
inhibition of complex I in mitochondria, and, possi-
bly, inhibition of the NADH oxidase of the plasma
membranes of cancerous cells [31], would seem to
inhibit the multidrug resistance (MDR) transporter
proteins which require ATP for energizing the P-gp
e¥ux pump [32,33]. Although our present study
showed little di¡erence in activity among acetogenins
with di¡erent stereochemical arrangements of the
THF rings, it was reported that the stereochemical
arrangement of the THF rings has slight e¡ect on the
activity with MCF-7/Adr cells [5], and, thus, this
assay has to take into consideration factors, such
1 The proposal for a model with multiple binding sites for
complex I inhibitors is primarily based on the earlier studies using
14C-labeled rotenone and piericidin A (Horgan et al., J. Biol.
Chem. 243 (1968) 834-843 and Gutman et al., J. Biol. Chem.
245 (1970) 1992^1997). However, these earlier studies were ques-
tioned by the recent radioligand assay using [3H]dihydrorotenone
(D.S. Higgins, J.T. Greenamyre, J., Neurosci. 16 (1996) 3807^
3816), wherein the signal-to-noise ratio was markedly improved
due to high speci¢c activity of the ligand.
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as membrane transport, intracellular transport and
metabolic inactivation.
Acknowledgements
The isolation of the acetogenins for this work was
supported, in part, by R01 Grant CA30909 from the
National Cancer Institute, National Institute of
Health.
References
[1] L. Zeng, Q. Ye, N.H. Oberlies, G. Shi, Z.-M. Gu, K. He,
J.L. McLaughlin, Nat. Prod. Rep. 13 (1996) 275^306.
[2] Z.-M. Gu, G.-X. Zhao, N.H. Oberlies, J.L. McLaughlin in:
J.T. Arnason, R. Mata, J.T. Romeo (Eds.), Recent Advances
in Phytochemistry, Vol. 29, Plenum Press, New York, 1995,
pp. 249^310.
[3] X.-P. Fang, M.J. Rieser, Z.-M. Gu, G.-X. Zhao, J.L.
McLaughlin, Phytochem. Anal. 4 (1993) 27^67.
[4] J.L. McLaughlin, L. Zeng, N.H. Oberlies, D. Alfonso, H.A.
Johnson, B.A. Cummings, in: P.A. Hedin, R.M. Holling-
worth, E.P. Masler, J. Miyamoto, D.G. Thompson (Eds.),
ACS Symposium Series, Phytochemicals for Pest Control,
658, American Chemical Society, Washington, DC, 1997,
pp. 117^133.
[5] N.H. Oberlies, C.-J. Chang, J.L. McLaughlin, J. Med.
Chem. 40 (1997) 2102^2106.
[6] M. Degli Esposti, A. Ghelli, M. Ratta, D. Cortes, E. Estor-
nell, Biochem. J. 301 (1994) 161^167.
[7] R.M. Hollingworth, K.I. Ahammadsahib, G. Gadelhak, J.L.
McLaughlin, Biochem. Soc. Trans. 22 (1994) 230^233.
[8] M.C. Gonzalez, J.R. Tormo, A. Bermejo, M.C. Zafra-Polo,
E. Estornell, D. Cortes, Bioorg. Med. Chem. Lett. 7 (1997)
1113^1118.
[9] T. Friedrich, P. Van Heek, H. Leif, T. Ohnishi, E. Forche,
B. Kunze, R. Jansen, W. Trowitzsch-Kienast, G. Ho«£e, H.
Reichenbach, H. Weiss, Eur. J. Biochem. 219 (1994) 691^
698.
[10] J.L. Landolt, K.I. Ahammadsahib, R.M. Hollingworth, F.L.
Barr, N.L. Crane, N.L. Buerck, G.P. McCabe, J.L.
McLaughlin, Chemico-Biol. Interact. 98 (1995) 1^13.
[11] E. Estornell, J.R. Tormo, D. Cortes, Biochem. Biophys. Res.
Commun. 240 (1997) 234^238.
[12] D. Alfonso, H.A. Johnson, T. Colman-Saizarbitoria, C.P.
Presley, G.P. McCabe, J.L. McLaughlin, Nat. Toxins 4
(1996) 181^188.
[13] H. Naito, E. Kawahara, K. Maruta, M. Maeda, S. Sasaki,
J. Org. Chem. 60 (1995) 4419^4427.
[14] S.C. Sinha, A. Sinha, A. Yazbak, Z. Keinan, J. Org. Chem.
61 (1996) 7640^7641.
[15] J.A. Marshall, K.W. Hinkle, J. Org. Chem. 62 (1997) 5989^
5995.
[16] J.A. Marshall, M. Chen, J. Org. Chem. 62 (1997) 5996^6000.
[17] H. Miyoshi, M. Inoue, S. Okamoto, M. Ohshima, K. Saka-
moto, H. Iwamura, J. Biol. Chem. 272 (1997) 16176^16183.
[18] A. Matsuno-Yagi, Y. Hate¢, J. Biol. Chem. 260 (1985)
14424^14427.
[19] T. Akagi, Y. Takahashi, S. Sasaki, Quant. Struct.-Act. Re-
lat. 15 (1996) 290^295.
[20] Y. Takahashi, T. Akagi, S. Sasaki, Tetrahedron Computer
Methodology 3 (1990) 27^35.
[21] H. Shimada, J.B. Grutzner, J.F. Kozlowski, J.L. McLaugh-
lin, Biochemistry 37 (1998) 854^866.
[22] N. Tokutake, H. Miyoshi, H. Nakazato, H. Iwamura, Bio-
chim. Biophys. Acta 1142 (1993) 262^268.
[23] K.H. Chung, K.Y. Cho, Y. Asami, N. Takahashi, S. Yoshi-
da, Z. Naturforsch. 44c (1989) 609^616.
[24] N. Tokutake, H. Miyoshi, T. Satoh, T. Hatano, H. Iwa-
mura, Biochim. Biophys. Acta 1185 (1994) 271^278.
[25] H. Miyoshi, N. Tokutake, Y. Imaeda, T. Akagi, H. Iwa-
mura, Biochim. Biophys. Acta 1229 (1995) 149^154.
[26] D.J. Horgan, H. Ohno, T.P. Singer, J.E. Casida, J. Biol.
Chem. 243 (1968) 5967^5976.
[27] G. Thierbach, B. Kunze, H. Reichenbach, G. Ho«£e, Bio-
chim. Biophys. Acta 765 (1984) 227^235.
[28] M. Degli Esposti, A. Ghelli, Biochim. Biophys. Acta 1187
(1994) 116^120.
[29] U. Brandt, Biochim. Biophys. Acta 1318 (1997) 79^81.
[30] K. He, L. Zeng, Q. Ye, G. Shi, N.H. Oberlies, G.-X. Zhao,
J. Njoku, J.L. McLaughlin, Pestic. Sci. 49 (1997) 372^378.
[31] J. Morre¤, R. DeCabo, C. Farley, N.H. Oberlies, J.L.
McLaughlin, Life Sci. 56 (1995) 343^348.
[32] S.M. Simon, M. Schindler, Proc. Natl. Acad. Sci. USA 91
(1994) 3497^3504.
[33] V. Ling, Cancer Res. 69 (1992) 2603^2609.
BBABIO 44643 9-7-98
H. Miyoshi et al. / Biochimica et Biophysica Acta 1365 (1998) 443^452452
